On the stock market since 2013, it operates in the world of health and science. It has 99 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 11% a year on average.
The company sells $532.3M a year; the problem isn’t sales — it’s costs running above that number.
There is $238.8M in the vault; even if every debt were paid off, $118.5M would remain.
A loss of $1.5M against $532.3M in annual sales.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, PHCUF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PHCUF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.